Gland Pharma · NSE: GLAND · BSE: 543245
Q2 FY26 results · Jul–Sep 2025
Gland Pharma reported revenue from operations of ₹1,486.88 crore (up 5.8% from Q2 FY25) and net profit of ₹183.68 crore (up 12.3% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,486.88 | 1,405.83 | +5.8% | 1,505.62 | −1.2% |
| Other income | 84.16 | 59.66 | +41.1% | 57.53 | +46.3% |
| Total income | 1,571.04 | 1,465.49 | +7.2% | 1,563.15 | +0.5% |
| Profit before tax | 283.92 | 256.78 | +10.6% | 312.74 | −9.2% |
| Net profit for the period | 183.68 | 163.53 | +12.3% | 215.48 | −14.8% |
| EPS, basic (₹) | 11.15 | 9.93 | +12.3% | 13.08 | −14.8% |
| Net margin (%) | 12.4 | 11.6 | 14.3 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,074.15 | 1,062.99 | +1.1% | 1,038.84 | +3.4% |
| Other income | 82.59 | 57.80 | +42.9% | 54.74 | +50.9% |
| Total income | 1,156.74 | 1,120.79 | +3.2% | 1,093.58 | +5.8% |
| Profit before tax | 408.67 | 379.82 | +7.6% | 362.38 | +12.8% |
| Net profit for the period | 302.00 | 281.71 | +7.2% | 269.26 | +12.2% |
| EPS, basic (₹) | 18.33 | 17.10 | +7.2% | 16.34 | +12.2% |
| Net margin (%) | 28.1 | 26.5 | 25.9 |
Consolidated
- Filed with BSE
- 03 Nov 2025, 21:14 IST
- Board meeting
- 03 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Nov 2025, 21:14 IST
- Board meeting
- 03 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE